Andrew Teasdale BSc, PhD

Andrew Teasdale PhD has over 20 years’ experience in the pharmaceutical industry as an analytical chemist and within quality assurance and regulatory roles. His current role is that of chair of AstraZeneca’s Impurity Advisory Board. He is a leading expert in key impurity areas, including mutagenic impurities (MIs), Elemental Impurities (EIs), Impurity qualification and Extractables and Leachables (E&Ls).

As well as his role in AZ he has led many cross industry groups relating to the areas described; these include both safety and quality groups within Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Extractables and Leachables Safety Information Exchange (ELSIE) and Product Quality Research Institute (PQRI). The latter focused on the critical area of sulfonate ester formation and control. He is also the editor/author of the first book on the subject of Genotoxic Impurities: Genotoxic Impurities – Strategies for Identification and Control (Wiley). He is also the inventor of the purge factor concept now routinely used in the evaluation of the potential carryover of mutagenic impurities.